SPRY 250117 7.50P (SPRY250117P7500) Stock Options, News & Quotes

0.10
0.000.00%

15min DelayClose Jan 17 16:00 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

This_Guy

Dec 19, 2024 16:31

$ARS Pharmaceuticals (SPRY.US)$
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
Positive
First FDA-approved needle-free epinephrine nasal spray
Rapid inclusion on Express Scripts Commercial National Formularies (9 weeks post-launch)
Access to millions of commercially insured patients
Superior product features: 30-month shelf-life, high temperature tolerance (122°F)
Negative
to patients weighing ≥30 kg (66 lbs.)
Current...

Green Dragon 2024

Nov 11, 2024 10:40

Additional info…

$ARS Pharmaceuticals (SPRY.US)$ comments from ALK CEO and sales projection. 🍾

Jaguar8

Nov 11, 2024 06:09

NEWS

$ARS Pharmaceuticals (SPRY.US)$
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
Agreement leverages ALK's global footprint in developing and commercializing innovative allergy products
ARS Pharma to receive an upfront cash payment of $145 million, with total deal consideration of up to $465 million plus double-digit royalties on net sales
ARS Pharma retains all U.S. rig...

Green Dragon 2024

Oct 24, 2024 10:48

News…

$ARS Pharmaceuticals (SPRY.US)$ Showcases Intranasal Epinephrine Data At 2024 American College Of Allergy, Asthma & Immunology Annual Scientific Meeting, Friday October 25.

Green Dragon 2024

Oct 23, 2024 04:33

Increase in shares…

$ARS Pharmaceuticals (SPRY.US)$